Video Series

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.

Kristin Highland, MD, discusses the common risk factors associated with ILD.

Paul Noble, MD, and Daniel Culver, DO, explain the definition of interstitial lung disease (ILD), as well as certain conditions that fall within that distinction.

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

An expert advises how to optimize the care continuum for patients with ASCVD.

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to access to care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.

A panel of experts elaborate on the decision support tools that are utilized by physicians to give patients high-value regimens.

The panel discusses the data used to evaluate healthcare resources for MM therapy, as well as economic burden.

Dr Beveridge provides a payer’s perspective on the available regimens for MM treatment.

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.

Muhamed Baljević, MD, FACP, provides a background of multiple myeloma (MM) within the past five years and the main treatment options.

Kashyap Patel, MD, and Jason Starr, DO, explain the potential changes providers might see in the future for MRD.

Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.

Our experts tell us how we can support the availability of MRD for more patients.

Dr Patel describes the importance of MRD in value-based care models.

Kashyap Patel, MD, and Jason Starr, DO, explain the various potential uses for MRD results and how they guide treatment decisions.

Jason Starr, DO, discusses MRD assessments, including: when they are done, where the testing takes place, and how often they are recommended.

The panel closes the program with giving their final thoughts on individualizing therapies for plaque psoriasis and metabolic syndrome in specific patient subpopulations.

Drs Lebwohl and Groves list support services to help with patient adherence.